SYDNEY, Feb 24, 2026, 18:20 AEDT — Market closed.
- Pro Medicus ended down 6.2% at A$108.15, after touching a fresh 52-week low
- Tech stocks led declines on the day, with investors still jittery over AI-driven disruption risks
- Traders are eyeing PME’s Feb 26 ex-dividend date for its 32-cent interim payout
Pro Medicus Ltd shares fell 6.2% to A$108.15 on Tuesday, extending a sharp pullback in high-priced software names and leaving the stock near the bottom of its 52-week range. The stock traded between A$107.75 and A$114.34. (Investing)
The slide came as Australia’s information technology sector dropped 3.5%, part of what one local market wrap called a “tech wreck” driven by worries about AI disruption. Xero fell 4.6% and Life360 slid 4.4%, while Telix Pharmaceuticals and Pro Medicus were among the day’s hardest-hit large caps. (Market Index)
The broader market held its ground. The S&P/ASX 200 ended almost flat at 9,022 points, down about 0.04%, as strength in resources offset the selling in growth and healthcare names. (ABC News)
For Pro Medicus holders, Tuesday’s fall followed a heavy Monday session. The stock closed at A$115.30 on Feb. 23, down 8.86% on the day, as volatility returned to the name after a long run where it was treated as a defensive growth play. (Market Index)
Dividend mechanics are also in view heading into the next session. A filing showed Pro Medicus will trade ex-dividend on Feb. 26 for an interim payout of A$0.32 a share, with a Feb. 27 record date and payment due March 20; the dividend is fully franked, meaning it carries Australian tax credits. (Company Announcements)
The company’s last set of numbers, released on Feb. 12, showed revenue from ordinary activities of A$124.8 million, up 28.4%, while underlying profit before tax rose 29.7% to A$90.7 million. Reported net profit after tax jumped to A$171.2 million, helped by unrealised gains linked to its investment in 4D Medical, the release said. (Market Index Data API)
Management has tried to draw a line between its business and the boom-bust around AI infrastructure and software tools. In an interview released with the results, chief executive Sam Hupert said: “Ours is a capital-light, software-only model. If anything, we will be the beneficiaries of the infrastructure funded by others.” (Company Announcements)
Still, the mood around tech has been ugly. The S&P/ASX 200 Tech Index was last flagged as trading at levels not seen since late 2023, and local desks are looking to the next wave of heavyweight earnings for direction. (Market Index)
But the dividend is not a floor. If the broader de-rating in software continues — or if investors keep treating “AI disruption” as a reason to cut risk first and ask questions later — Pro Medicus can stay tied to the tape even without fresh company news.
Next up, traders will watch how the market prices PME into Thursday’s ex-dividend date, and whether upcoming results from other large ASX growth names shift sentiment back toward — or further away from — high-multiple software.
